2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary
| Autor: | L. de la Cruz-Merino, Carmen Balana, Ángel Concha, Xavier Matias-Guiu, Lara Iglesias, V. Fusté, B. Nieto, Julián Sanz, M. Pané, Ferran Losa |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Consensus Statement (logic) Biopsy MEDLINE Histopathology Review Article Medical Oncology Metastasis Cancer of unknown primary 03 medical and health sciences 0302 clinical medicine Metàstasi Diagnosis medicine Humans Chemotherapy Càncer Pathological Societies Medical Aged Cancer Molecular pathology Pathology Clinical business.industry General Medicine Middle Aged medicine.disease Prognosis Immunohistochemistry 3. Good health 030104 developmental biology Oncology Spain 030220 oncology & carcinogenesis Family medicine Neoplasms Unknown Primary business Separate legal entity |
| Zdroj: | Recercat. Dipósit de la Recerca de Catalunya instname Dipòsit Digital de la UB Universidad de Barcelona Clinical & Translational Oncology Recercat: Dipósit de la Recerca de Catalunya Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) Repositorio Abierto de la UdL Universitad de Lleida Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
| Popis: | Cancer of unknown primary (CUP) is defned as a heterogeneous group of tumours that present with metastasis, and in which attempts to identify the original site have failed. They difer from other primary tumours in their biological features and how they spread, which means that they can be considered a separate entity. There are several hypotheses regarding their origin, but the most plausible explanation for their aggressiveness and chemoresistance seems to involve chromosomal instability. Depending on the type of study done, CUP can account for 2–9% of all cancer patients, mostly 60–75 years old. This article reviews the main clinical, pathological, and molecular studies conducted to analyse and determine the origin of CUP.The main strategies for patient management and treatment, by both clinicians and pathologists, are also addressed. The authors are grateful for the editorial assistance of Dr. Fernando Sánchez-Barbero of HealthCo (Madrid, Spain) in the production of this manuscript. SEOM and SEAP are grateful for the fnancial support for this project in the form of unrestricted grants from Ferrer Diagnostic, OncoDNA and Foundation Medicine/Roche. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|